Now I have a thorough understanding of the paper and the reviewer inputs. Let me produce the final consolidated review.

---

## Summary

PharmaVQA proposes a molecular representation learning framework that uses a Visual Question Answering (VQA) formulation with bilinear attention (BAN) to extract pharmacophore-related features from molecular graphs. By designing questions about pharmacophore counts and supervising with RDKit-derived labels, the model produces "knowledge prompts" that are concatenated with graph embeddings for downstream tasks. The paper evaluates on property prediction (Li, MoleculeACE), drug-target interaction (BindingDB), and ligand discovery (HPK1, FGFR1, VIM-1), claiming superior performance across 46 datasets.

## Strengths

- **Novel integration of VQA with pharmacophore-guided molecular representation.** Unlike prior methods that use self-supervised pretraining or generic knowledge injection (e.g., KPGT), PharmaVQA formulates pharmacophore counting as a VQA task (Section 5.2: "instead of asking whether pharmacophores exist... we ask how many are present") and uses bilinear attention to produce pharmacophore-specific features. This is a distinct and creative approach to incorporating domain knowledge into molecular representations.

- **Novel alignment loss guiding attention toward pharmacophore-relevant substructures.** The paper introduces an alignment loss (Equation 11) that compares the BAN-derived node-importance matrix against an RDKit-derived ground-truth matrix indicating which atoms belong to each functional group. This provides a principled training signal that explicitly encourages the model to attend to the correct molecular substructures, beyond what standard task losses achieve.

- **Broad evaluation scope across multiple drug-discovery tasks.** The paper evaluates on molecular property prediction (11 Li datasets + 30 MoleculeACE datasets), drug-target interaction (BindingDB classification and regression), and ligand discovery (3 targets). This breadth suggests the pharmacophore-enriched representations generalize beyond a single benchmark, lending support to the claim of broad applicability.

## Weaknesses

### Major

- **Drug–target interaction architecture is completely unspecified, making the BindingDB results unverifiable.** The paper claims "superior performance" on BindingDB classification and regression (Section 5.4) but never describes how protein information is encoded or fused with the molecular representation. Section 4 describes only a molecular graph encoder and a text encoder (SciBERT), while Section 4.4 defines the fused embedding $\hat{y}=MLP(concat(f, H_{\mathcal{G}}'))$ — with no protein representation in sight. For BindingDB, which explicitly involves drug–target pairs, the model must somehow incorporate the protein. The paper does not explain whether a separate protein encoder is used, how the pair is formed, or how the task-specific prediction head works. Without this, the DTI results cannot be interpreted or verified.

- **Ligand screening protocol is critically underspecified.** The paper reports that for HPK1, FGFR1, and VIM-1, 10, 15, and 16 of the Top‑20 predictions are "experimentally validated as potential ligands previously reported in the literature" (abstract and Section 5.5). However, the screening procedure is not described: (a) which model variant produces the ranking? (b) what is the ranking criterion — predicted affinity, predicted property, or a separate scoring function? (c) what is the exact candidate molecule set (FDA-approved, DrugBank, or something else)? (d) how was "validated by literature" determined and what constitutes evidence? Without this information, the reader cannot assess whether the results reflect genuine predictive power, trivial retrieval of known ligands, or circular validation. The comparison to KPGT (12/13 for HPK1/FGFR1) further requires the screening sets and criteria to be identical, which is not established.

### Minor

- **Results are not summarized in the prose, forcing reliance on table images for central claims.** The paper states "superior performance on 46 benchmark datasets" and "top-level performance" on BindingDB (Section 5.4), but does not report any actual AUC, RMSE, R², or comparison numbers in the text. All quantitative results appear only in table images. While the tables exist, the absence of any textual summary of the magnitude of improvements, statistical significance, or comparison to baselines makes the central SOTA claim harder to evaluate. If the table images were unavailable or illegible, the claim would be entirely unsupported in the prose.

- **Interpretability case study provides weak evidence of pharmacophore understanding.** The case study (Section 5.6, Figure 3) shows that for a question about "donor" pharmacophores, the attention map highlights words like "hydrogen", "bond", and "donors" — all of which appear explicitly in the question text. Any reasonable text-aware attention mechanism would weight these words highly, regardless of whether the model has learned meaningful molecular pharmacophore information. This does not demonstrate that the model understands molecular structure beyond keyword matching. A stronger test would examine whether the model attends to different text tokens when the molecule changes but the question stays the same.

- **Key architectural design choices are not explained.** Section 4.4 introduces a second graph encoder ($Encoder_g'$) that produces $H_{\mathcal{G}}'$ for the final prediction, but the paper does not explain: (a) whether the two encoders share parameters or are trained jointly, (b) why a separate encoder is needed instead of reusing the first encoder's output, and (c) whether there is a risk of gradient interference or double-counting. This omission obscures the model's actual parameter count and training dynamics.

- **The paper does not mention code availability or dataset splits.** For a method with a custom multi-loss training objective, custom attention mechanism, and multiple evaluation protocols, this limits reproducibility. The paper borrows splits from prior work (Li et al., 2023a; Song et al., 2023) but does not confirm that the exact same splits were used for BindingDB comparisons.

### Trivial

- The term "retrieval-augmented" is used loosely. The model does not query an external database; it uses BAN-based attention to extract features from the molecule's own graph representation. This is feature extraction via cross-modal attention, not retrieval in the conventional sense.
- The mapping from P questions (14, for 7 pharmacophores × 2 questions) to the P functional groups in the alignment loss matrix $O \in \mathbb{R}^{n,P}$ (Equation 11) could be clarified. The paper states 7 pharmacophores with 2 questions each (Section 5.2) but the loss description in Section 4.5 discusses P functional groups without explaining how multiple questions per group are handled.

## Nice-to-Haves

- An ablation study quantifying the contribution of each loss component ($L_{ph}$, $L_{align}$) and the number of questions would help attribute the gains to the VQA attention mechanism vs. multi-task training vs. increased model capacity.
- Runtime and parameter count comparisons would help readers assess the practical cost of using two graph encoders and per-molecule, per-question bilinear attention.

## Removed Points

The following points from reviewers were removed or corrected per the review guidelines:

- **"46 vs. 43 dataset discrepancy"** — The reviewer counted 11 (Li) + 30 (MoleculeACE) + 2 (BindingDB) = 43, but omitted the 3 ligand datasets (HPK1, FGFR1, VIM-1) listed in Section 5.1. The total is 11 + 30 + 2 + 3 = 46, consistent with the abstract. (Factually incorrect.)
- **Requests for specific hyperparameter values (α, β, number of glimpses S)** — These are standard hyperparameter details whose omission does not invalidate the core claims. (Per guidelines: remove nitpicks about undisclosed hyperparameters.)
- **Training schedule and optimization details** — Standard implementation details impractical to fully specify in a conference paper. (Per guidelines: remove nitpicks about trivial implementation details.)
- **"Knowledge prompt" terminology complaint** — This is a stylistic preference about terminology, not a substantive weakness. (Removed as a style nitpick.)

## Novel Insights

The most interesting observation from cross-referencing the reviews is the tension between the paper's claimed "retrieval-augmented" framing and its actual mechanism. The paper applies BAN — a VQA fusion method designed for images and text — to a molecular graph and text questions, which is genuinely novel in the molecular representation space. However, the "retrieval" claim sets up expectations that the paper does not meet (no external knowledge base querying, no database retrieval), and this mismatch between framing and mechanism likely caused reviewer confusion. Separately, the DTI architecture gap is the single most consequential issue: it is unlikely that the model handles BindingDB without any protein encoding at all, yet the paper simply omits this component from the method description. If the authors have a straightforward way to incorporate protein information (e.g., a separate protein GNN whose output is concatenated with the molecule embedding), the entire DTI section becomes interpretable and the main weakness is resolved.

## Suggestions

1. **Describe the DTI architecture explicitly.** Add a subsection explaining how protein information is encoded (e.g., a protein GNN or sequence encoder), how the drug and protein representations are fused, and what prediction head is used for BindingDB classification vs. regression. Without this, the DTI results cannot be trusted.
2. **Specify the ligand screening protocol in full.** Describe: the model variant used for ranking; the ranking criterion (predicted property, docking score, or other); the exact candidate molecule set and its size; and the literature validation procedure (search methodology, what constitutes "validated").
3. **Add a textual summary of main results** (mean AUC/RMSE/R² with standard deviations and best baseline) so the SOTA claim is verifiable without relying on table images.
4. **Clarify the two-encoder design** — whether parameters are shared, why a separate encoder is needed, and the total parameter count.
5. **Provide ablation experiments** disentangling the contributions of $L_{ph}$, $L_{align}$, and the number of pharmacophore questions, to verify that the gains come from the VQA-guided attention rather than increased model capacity or multi-task training.

## Score and Decision

The paper presents a genuinely novel idea (VQA-style bilinear attention for pharmacophore-guided molecular representation) with a broad evaluation. However, two major weaknesses — the completely unspecified DTI prediction architecture and the critically underspecified ligand screening protocol — mean that significant portions of the claimed empirical validation are unverifiable. The DTI and ligand discovery claims are central to the paper's headline contributions (abstract lists both). These issues cannot be resolved in a conference rebuttal and require substantial rewriting/clarification of the method and experimental protocols. The core molecular representation idea has promise, but in its current form the paper does not provide enough information to validate key results.

**Score:** 4.5 (Weak Reject — major gaps in methodology description and experimental validation that prevent verification of central claims)

MY FINAL SCORE: <pineapple>4.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>